

07th July 2026

To

The BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001
Scrip Code: 517556

National Stock Exchange of India Limited
“Exchange Plaza, Bandra Kurla Complex,
Bandra (E)
Mumbai - 400051
Symbol: PVP
Debt-18PVL29A, 18PVL29

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Completion of Further Acquisition of Stake in 7 Med India Private Limited

In continuation of our earlier intimations dated 28th August 2025 and 4th November 2025 regarding the acquisition of an equity stake in 7 Med India Private Limited, we wish to inform you that the company has successfully completed the acquisition of an additional 4,263 equity shares of 7 Med India Private Limited.

Pursuant to the aforesaid acquisition, the company’s shareholding in 7 Med India Private Limited has increased to 41.23% of the total paid-up share capital of the target company.

This acquisition has been completed in accordance with the terms of the Share Purchase Agreement and the Shareholders’ Agreement executed between the parties, and forms part of the company’s strategic investment in the healthcare sector. The company remains committed to completing the balance acquisition in terms of the definitive agreements executed between the parties.

The brief details, as required under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in accordance with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024, are enclosed herewith as **Annexure A**.

Request you to kindly take the same on record.

For PVP Ventures Limited

Prasad V Potluri
Chairman & Managing Director

Attached: As in above

Annexure A

Details required to be provided while disclosing an event under Regulation 30, Para A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024:

S.NO	PARTICULARS	DETAILS
1	Name of the target entity, details in brief such as size, turnover etc.;	7Med India Pvt. Ltd. 7Med India Pvt Ltd is among the top five organized players in India's renal care sector, offering a comprehensive range of dialysis services across its pan-India network.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	The acquisition does not fall within the ambit of a related party transaction. It has been undertaken in accordance with the transaction documents executed by the Company, including the Share Purchase Agreement and Shareholders' Agreement, and is on an arm's length basis. This acquisition represents the second tranche of the transaction, the first tranche having been completed on 4th November 2025, pursuant to which 7 Med India Private Limited became an associate company of the Company. Other than the shareholding disclosed above, none of the promoter/promoter group/group companies have any interest in the entity being acquired.
3	Industry to which the entity being acquired belongs;	Healthcare
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The acquisition is in furtherance of the company's strategic expansion into the healthcare sector.

5	Brief details of any governmental or regulatory approvals required for the acquisition;	Nil
6	Indicative time period for completion of the acquisition;	The acquisition of the additional 4,263 equity shares, taking the Company's shareholding to 41.23%, has been completed. The balance shareholding, to take the Company's aggregate stake to 50.62%, is expected to be completed in accordance with the terms of the definitive agreements executed between the parties.
7	Consideration -whether cash consideration or share swap or any other form and details of the same;	Cash consideration.
8	Cost of acquisition and/or the price at which the shares are acquired	The transaction shall be a combination of both primary and secondary stake purchase amounting to an outlay of circa INR 127 crores for this majority shareholding (50.62%).
9	Percentage of shareholding / control acquired and / or number of shares acquired	Acquisition of 4,263 equity shares resulting in an increase in shareholding to 41.23% of the paid-up share capital of 7 Med India Private Limited.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	7Med India Pvt Ltd is among the top five organized players in India's renal care sector, offering a comprehensive range of dialysis services across its pan-India network.

For PVP Ventures Limited

Prasad V Potluri
Chairman & Managing Director